文献速递重症综合管理与镇静镇痛心脑血管急症复苏、休克与脓毒症

治愈昏迷运动国际调查:昏迷的流行病学、评估与治疗(COME TOGETHER)

The Curing Coma Campaign International Survey on Coma Epidemiology, Evaluation, and Therapy (COME TOGETHER).
PubMed 文献 · Neurocrit Care · 2022-02-09
一句话结论全球258名医护人员调查显示昏迷定义与处理差异大,GCS和神经检查最常用,高级评估技术使用有限,出院后随访不足。

作为神经重症学会治愈昏迷运动的一部分,2020年9月至2021年1月开展匿名国际横断面调查,覆盖41个国家258名医护人员,多数为医师(83%)、来自美国(55%)和学术中心(90%)。受访者对昏迷核心特征组合不一:无觉醒(81%,κ=0.764)、GCS≤8(64%,κ=0.588)、不能对视觉/言语/触觉刺激有目的反应(60%,κ=0.552)、不能遵嘱(58%,κ=0.529)。常见病因为药物诱导昏迷(24%)、创伤性脑损伤(24%)、脑出血(21%)、心脏骤停/缺氧缺血性脑病(11%)。常用评估工具为GCS(94%)和神经检查(78%),66%常规进行镇静中断。高级评估技术使用率低,神经兴奋药以金刚烷胺(51%)最常见。出院后随访不足20%,但86%有兴趣参与未来研究。结论认为昏迷定义和处理存在广泛异质性,亟需循证指南和协调方法。

要点

  • 昏迷定义无统一标准:无觉醒81%(κ=0.764)、GCS≤8 64%(κ=0.588)、不能有目的反应60%(κ=0.552)、不能遵嘱58%(κ=0.529)。
  • 最常见昏迷病因为药物诱导昏迷(24%)和创伤性脑损伤(24%),其次脑出血(21%)、心脏骤停/缺氧缺血性脑病(11%)。
  • 临床评估以GCS(94%)和神经检查(78%)为主;66%受访者在无禁忌时常规中断镇静以评估昏迷。
  • 高级神经评估技术使用有限:定量EEG/连接分析16%、功能MRI 7%、SPECT 6%、PET 4%、侵入性EEG 4%、脑微透析4%。
  • 神经兴奋药常用金刚烷胺(51%)、莫达非尼(37%)、哌甲酯(28%);出院后常规随访不足20%,但86%有兴趣参与未来研究。

适用人群与场景

  • 在急性、亚急性或慢性阶段照护昏迷及意识障碍患者的医护人员,来自41个国家,共258人。
  • 受访者以医师为主(n=213,83%),多来自美国(n=141,55%)和学术中心(n=231,90%)。

诊断标准与关键阈值

  • 昏迷核心特征(八项预设条目中受访者选择的不同组合):无觉醒(81%,κ=0.764)、GCS≤8(64%,κ=0.588)、不能对视觉、言语或触觉刺激有目的反应(60%,κ=0.552)、不能遵嘱(58%,κ=0.529)。

处置流程与药物剂量

  • 66%的受访者在无禁忌证时,为在ICU进行临床昏迷评估而常规中断镇静。
  • 昏迷常用临床评估工具:GCS(94%)、神经检查(78%)。
  • 高级神经评估技术:定量脑电图/连接分析(16%)、功能磁共振成像(7%)、单光子发射计算机断层扫描(6%)、正电子发射断层扫描(4%)、侵入性脑电图(4%)、脑微透析(4%)。
  • 最常用的神经兴奋药:金刚烷胺(51%)、莫达非尼(37%)、哌甲酯(28%)。
  • 预后判断的主要决定因素包括昏迷病因、神经检查发现和神经影像。

研究设计与关键结果

  • 研究类型:神经重症学会治愈昏迷运动发起的匿名国际横断面调查,2020年9月至2021年1月通过国际神经科学学会连续邮件和社交媒体发放。
  • 样本量与人群:共258名医护人员完成调查,来自41个国家;医师213人(83%),美国141人(55%),学术中心231人(90%)。
  • 主要结果:昏迷定义的核心特征选择存在异质性(无觉醒81%,κ=0.764;GCS≤8 64%,κ=0.588;不能有目的反应60%,κ=0.552;不能遵嘱58%,κ=0.529)。
  • 病因构成:药物诱导昏迷24%、创伤性脑损伤24%、脑出血21%、心脏骤停/缺氧缺血性脑病11%。
  • 评估与处理:GCS使用率94%,神经检查78%;66%常规中断镇静;高级评估技术使用率16%至4%不等;神经兴奋药金刚烷胺51%、莫达非尼37%、哌甲酯28%。
  • 随访:不足20%的受访者对昏迷幸存者出院后常规随访;86%表示有兴趣参与未来包含出院后6个月(85%)和12个月(65%)结局的研究。

证据类型、等级与局限

  • 证据类型:国际横断面调查(治愈昏迷运动)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 调查显示昏迷的临床定义和处理在不同医护人员间存在广泛异质性,急性照护机构中高级昏迷评估技术常规使用有限。
  • 昏迷管理实践因地点而异,急性治疗后的协调持续随访机制不一致。
  • 作者认为亟需制定循证指南并采取协作、协调的方法,以推动全球昏迷管理的科学与实践。

指南或共识出处

  • Neurocritical Care Society Curing Coma Campaign

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Although coma is commonly encountered in critical care, worldwide variability exists in diagnosis and management practices. We aimed to assess variability in coma definitions, etiologies, treatment strategies, and attitudes toward prognosis.

METHODS: As part of the Neurocritical Care Society Curing Coma Campaign, between September 2020 and January 2021, we conducted an anonymous, international, cross-sectional global survey of health care professionals caring for patients with coma and disorders of consciousness in the acute, subacute, or chronic setting. Survey responses were solicited by sequential emails distributed by international neuroscience societies and social media. Fleiss κ values were calculated to assess agreement among respondents.

RESULTS: The survey was completed by 258 health care professionals from 41 countries. Respondents predominantly were physicians (n = 213, 83%), were from the United States (n = 141, 55%), and represented academic centers (n = 231, 90%). Among eight predefined items, respondents identified the following cardinal features, in various combinations, that must be present to define coma: absence of wakefulness (81%, κ = 0.764); Glasgow Coma Score (GCS) ≤ 8 (64%, κ = 0.588); failure to respond purposefully to visual, verbal, or tactile stimuli (60%, κ = 0.552); and inability to follow commands (58%, κ = 0.529). Reported etiologies of coma encountered included medically induced coma (24%), traumatic brain injury (24%), intracerebral hemorrhage (21%), and cardiac arrest/hypoxic-ischemic encephalopathy (11%). The most common clinical assessment tools used for coma included the GCS (94%) and neurological examination (78%). Sixty-six percent of respondents routinely performed sedation interruption, in the absence of contraindications, for clinical coma assessments in the intensive care unit. Advanced neurological assessment techniques in comatose patients included quantitative electroencephalography (EEG)/connectivity analysis (16%), functional magnetic resonance imaging (7%), single-photon emission computerized tomography (6%), positron emission tomography (4%), invasive EEG (4%), and cerebral microdialysis (4%). The most commonly used neurostimulants included amantadine (51%), modafinil (37%), and methylphenidate (28%). The leading determinants for prognostication included etiology of coma, neurological examination findings, and neuroimaging. Fewer than 20% of respondents reported routine follow-up of coma survivors after hospital discharge; however, 86% indicated interest in future research initiatives that include postdischarge outcomes at six (85%) and 12 months (65%).

CONCLUSIONS: There is wide heterogeneity among health care professionals regarding the clinical definition of coma and limited routine use of advanced coma assessment techniques in acute care settings. Coma management practices vary across sites, and mechanisms for coordinated and sustained follow-up after acute treatment are inconsistent. There is an urgent need for the development of evidence-based guidelines and a collaborative, coordinated approach to advance both the science and the practice of coma management globally.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Helbok R, Rass V, Beghi E, et al. The Curing Coma Campaign International Survey on Coma Epidemiology, Evaluation, and Therapy (COME TOGETHER). Neurocrit Care. 2022. PMID: 35141860. doi:10.1007/s12028-021-01425-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。